These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1905083)

  • 1. Combined solvent-detergent and 100 degrees C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility.
    Rubinstein AI; Rubinstein DB; Coughlin J
    Vox Sang; 1991; 60(1):60. PubMed ID: 1905083
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermal inactivation by sequential dry-heat treatments at sterilizing temperatures (100 degrees C-boiling) of factor VIII and factor IX concentrates to produce sterile concentrates.
    Rubinstein AI; Rubinstein DB
    Vox Sang; 1989; 57(4):272. PubMed ID: 2515655
    [No Abstract]   [Full Text] [Related]  

  • 4. Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment.
    Rubinstein AI; Rubinstein DB
    Am J Hematol; 1990 Oct; 35(2):142. PubMed ID: 2119141
    [No Abstract]   [Full Text] [Related]  

  • 5. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation of two factor VIII concentrates virally inactivated by solvent-detergent or by pasteurization.
    Peerlinck K; Arnout J; Tamise M; Vanherle A; Fondu P; Vermylen J
    Acta Clin Belg; 1991; 46(5):298-304. PubMed ID: 1661550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
    Branović K; Gebauer B; Trescec A; Benko B
    Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
    Teh LC
    Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
    Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
    Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
    Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
    J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
    Roberts PL; Hart H
    Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP; Rice KM; Savidge GF
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
    Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
    Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
    Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
    Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat sterilisation to inactivate AIDS virus in lyophilised factor VIII.
    Margolis J; Li ZP
    Aust N Z J Med; 1986 Jun; 16(3):413. PubMed ID: 3096270
    [No Abstract]   [Full Text] [Related]  

  • 17. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary clinical experience: pharmacokinetics and tolerance of a double-virus-inactivated factor VIII preparation.
    Martinowitz U
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S84-5. PubMed ID: 7495976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
    Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
    Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
    Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
    Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.